{"entity":{"id":"nct07767474","kind":"trial","name":"A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ATX-898 run by Antares Therapeutics, Inc, now recruiting.","summary":"A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07767474 by Antares Therapeutics, Inc, with 343 participants planned, started 2026-08-31. Conditions recorded: Advanced Solid Tumors. Interventions recorded: ATX-898, ATX-898, ATX-898, ATX-898, ATX-898, ATX-898, fulvestrant, ribociclib, ATX-898, fulvestrant, ribociclib and ATX-898, fulvestrant, ribociclib.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07767474","url":"https://clinicaltrials.gov/study/NCT07767474"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["atx-898"],"companies":["antares-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07767474","phase":"1/2","setting":"First-in-human Study of ATX-898, as Monotherapy and in Combination With Other Anti-neoplastic Agents, in Participants With Advanced Solid Tumors","sponsor":"Antares Therapeutics, Inc","enrolled":343,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07767474/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"atx-898","kind":"drug","name":"ATX-898","route":"/drugs/atx-898/"}],"company":[{"id":"antares-therapeutics","kind":"company","name":"Antares Therapeutics","route":"/companies/antares-therapeutics/"}]}}